Frontlight ResearchEarly access
CompletedNo phase
AI Evaluation of Pancreatic Exocrine Insufficiency in CP Patients
Key facts
- Who runs it
- Changhai Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 504 people enrolled
- Started
- 1 Mar 2023
- Ended
- 1 Jan 2024
- Type of study
- Observational
- Record updated
- 26 February 2024
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- gender and age are not restricted
- diagnosis of chronic pancreatitis
- fe-1 test was conducted following recent pancreatic enhanced CT
- sign informed consent
Who cannot take part
- previous pancreatic surgery
- history of malignant tumor
- systemic diseases
- enhanced CT was taken during the acute episode of chronic pancreatitis
- poor image quality or image loss
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Early assessment of pancreatic exocrine insufficiency (PEI) is crucial for determining appropriate chronic pancreatitis (CP) treatment plans, thereby avoiding unnecessary suffering and further complications in patients. A total of 504 patients with CP who underwent fecal elastase-1 test and contrast-enhanced CT at Changhai Hospital between January 2018 and April 2023 were enrolled in this study. The investigators aim to establish a fully automated workflow to establish a PEI classification model based on radiomic features, semantic features and deep learning features on enhanced CT images for evaluating the severity of PEI.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Artificial Intelligence Assistance of Pancreatic Exocrine Insufficiency Evaluation in Chronic Pancreatitis From Contrast-Enhanced CT
- Record updated
- 26 February 2024